Key scientific achievement advances the joint neuroscience pipeline and earns a payment of US$ 25 m to Evotec to progress further research.

Innovative Photonic Solutions (IPS), Inc., a member of the Metrohm group and the m-oem portfolio of companies, recently manufactured its 40,000th laser.

Azenta Life Sciences reports how the two-component design of its FrameStar® microplate range reduces thermal expansion and sample evaporation leading to improved consistency of PCR results.

Annexin V Starbright™ conjugates offer increased choice and flexibility for apoptosis detection in conventional and full spectrum flow cytometry.

Cresset, announces an extension of the global collaboration with Enamine, in the area of targeted protein degradation (TPD).

AMSBIO has published an informative online article that reviews the importance of culture techniques for induced pluripotent stem cells (iPSCs), which provide an invaluable resource for drug discovery and therapeutic applications.

BioSpring GmbH and Pantherna Therapeutics GmbH, have agreed on a strategic collaboration in the field of research and development and signed a cooperation agreement mid-July.

On July 29, 2024, the U.S. FDA approved Alpha Cognition Inc.'s ALPHA-1062 (Zunveyl®), an Acetylcholinesterase (AChE) inhibitor, for treating mild-to-moderate Alzheimer’s disease.

On June 14, 2024, the U.S. FDA approved AstraZeneca's Durvalumab (IMFINZI®) for primary advanced or recurrent endometrial cancer with mismatch repair deficiency.

The long-term PERFECT observational study follows patients from successful Phase I/IIb of ProtheraCytes for the repair and regeneration of damaged cardiac tissues after severe heart attack.